<DOC>
	<DOCNO>NCT02137850</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate safety efficacy turoctocog alfa pegol ( N8-GP ) previously untreated patient ( PUPs ) haemophilia A .</brief_summary>
	<brief_title>Safety Efficacy Turoctocog Alfa Pegol ( N8-GP ) Previously Untreated Patients With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Male , age 6 year age time sign informed consent Diagnosis severe haemophilia A ( FVIII activity level 1 % ) base medical record central laboratory result No prior use purify clot factor product ( 5 previous exposure blood component acceptable ) Any history FVIII inhibitor ( define medical record ) Known suspect hypersensitivity trial product relate product Previous participation trial . Participation define first dose administer trial product Receipt investigational medicinal product within 30 day screen Congenital acquire coagulation disorder haemophilia A Any chronic disorder severe disease , opinion Investigator , might jeopardise patient 's safety compliance protocol Patient 's parent ( ' ) /legally acceptable representative ( LAR ( ' ) ) mental incapacity , unwillingness cooperate , language barrier preclude adequate understanding cooperation</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>